Alzheimer’s Disease and Other Autoimmune Degenerative Conditions: The Mercury Connection

0 Flares Twitter 0 Facebook 0 Google+ 0 LinkedIn 0 0 Flares ×

There has been a huge increase in the incidence of degenerative neurological conditions in virtually all western countries over the last few decades. Alzheimer’s disease is the leading cause of dementia in the elderly. The increase in Alzheimer’s and other dementia has been over 300%. The primary cause appears to be brain inflammation related to increased exposures to toxic pollutants and bad dietary habits, as well as oxidative stress and depletion of neurotransmitters such as acetylcholine. These appear to be factors in formation of advanced glycation end products (AGEs) and senile plaques of beta-amyloid peptides, hyper-phosphorylation of Tau, and neurofibrillary tangles-as seen in Alzheimer’s patients.

Mercury is known to be one of the most toxic substances commonly encountered and to be along with leading the toxic substances adversely affecting the largest numbers of people. Mercury in the presence of other metals in the oral environment undergoes galvanic action, causing movement out of amalgam and into the oral mucosa and saliva. Mercury in solid form is not stable due to its vapor pressure and oral galvanism of mixed metals so that it evaporates continuously from amalgam fillings in the mouth, being transferred over a period of time to the host. The daily total exposure of mercury from fillings is from 3 to 1000 micrograms per day, with the average exposure for those with several fillings being above 30 micrograms per day and the average uptake over 7 ug/day, with the majority of the rest excreted through the feces and often being over 30 ug/day. The average amount of mercury in the feces of a group with amalgams was over 10 times that of controls. A 2009 study found that inorganic mercury levels in people have been increasing rapidly in recent years. It used data from the U.S. Centers for Disease Control and Prevention’s National Health Nutrition Examination Survey (NHANES) finding that, while inorganic mercury was detected in the blood of 2 percent of women aged 18 to 49 in the 1999-2000 NHANES survey, the level rose to 30 percent of women by 2005-2006.

Surveys in all states using hair tests have found dangerous levels of mercury in an average of 22% of the population, with over 30% in some states like Florida and New York. A large U.S. Centers for Disease Control epidemiological study, NHANES III, found that those with more amalgam fillings (more mercury exposure) have significantly higher levels of chronic health conditions. Amalgam fillings are the largest source of mercury in most people with daily exposures documented to commonly be above government health guidelines. This is due to continuous vaporization of mercury from amalgam in the mouth, along with galvanic currents from mixed metals in the mouth that deposit the mercury in the gums and oral cavity. Due to the high daily mercury exposure and excretion into home and business sewers of those with amalgam, dental amalgam is also the largest source of the high levels of mercury found in all sewers and sewer sludge, and thus according to government studies a significant source of mercury in rivers, lakes, bays, fish, and crops. People also get significant exposure from vaccinations, fish, and dental office vapor.

When amalgam was placed into teeth of monkeys and rats, within one year mercury was found to have accumulated in the brain, trigeminal ganglia, spinal ganglia, kidneys, liver, lungs, hormone glands, and lymph glands. People commonly are exposed to mercury and other toxic metals, such as lead, arsenic, nickel, and aluminum from food, water, and other sources. All of these are highly neurotoxic and are documented to cause neurological damage which can result in chronic neurological conditions over time, as well as ADHD, mood, and behavioral disorders.

Another major source of mercury exposure is vaccines such as flu vaccines, which have large amounts of mercury and aluminum and have been linked to conditions like depression, Parkinson’s, ALS, and dementia. It has been found that vaccines contain adjuvants like aluminum plus mercury thimerosal which overstimulate the immune system and brain, causing high levels of inflammation over long periods of time. There is evidence of a link between the aluminum hydroxide in vaccines, and symptoms associated with Alzheimer’s, Parkinson’s, and ALS. It has been found that those who get at least five flu shots have an increased risk of inflammatory conditions like Alzheimer’s of at least 500%.

Mercury is one of the most toxic substances in existence and is known to bio-accumulate in the body of people and animals that have chronic exposure. Mercury exposure is cumulative and comes primarily from four main sources: mercury amalgam dental fillings, food (mainly fish), vaccinations, and occupational exposure. Whereas mercury exposure from fish is primarily methylmercury and mercury from vaccinations is thimerosal (ethylmercury), mercury from occupational exposure and dental fillings is primarily from elemental mercury vapor. However, bacteria, yeasts, and Vitamin B12 methylate inorganic mercury to methylmercury in the mouth and intestines and mercury inhibits functional methylation in the body, a necessary process. Developmental and neurological conditions occur at lower levels of exposure from mercury vapor than from inorganic mercury or methylmercury. Mercury in amalgam fillings because of its low vapor pressure and galvanic action with other metals in the mouth, has been found to be continuously vaporized and released into the body, and has been found to be the directly correlated to the number of amalgam surfaces and the largest source of mercury in the majority of people, typically between 60 and 90% of the total.

The level of daily exposure of those with several amalgam fillings commonly exceeds the U.S. EPA health guideline for daily mercury exposure of 0.1 ug/kg body weight/day, and the oral mercury level commonly exceeds the mercury MRL of the U.S. ATSDR of 0.2 ug/ cubic meter of air. When amalgam fillings are replaced, levels of mercury in the blood, urine, and feces typically rise temporarily but decline between 60 to 85% within 6 to 9 months.

Cytotoxic, Neurotoxic, and Immunotoxic Effects of Mercury

Mercury vapor from amalgam readily crosses cell membranes and binds to the -SH (sulphydryl) groups, resulting in inactivation of sulfur processes and blocking of enzyme functions such as cysteine dioxygenase (CDO), sulfite oxidase, and gamma-glutamyltraspeptidase(GGC), producing sulfur metabolites with extreme toxicity that the body is unable to properly detoxify, along with a deficiency in sulfates required for many body functions. Sulfur is essential in enzymes, hormones, nerve tissue, and red blood cells. These exist in almost every enzymatic process in the body. Blocked or inhibited sulfur oxidation at the cellular level has been found in most with many of the chronic degenerative diseases, including Parkinson’s, Alzheimer’s, ALS, MS, lupus, rheumatoid arthritis, MCS, etc., and appears to be a major factor in these conditions. The deficiency in conjugation and detoxification of sulfur based toxins in the liver results in toxic metabolites and progressive nerve damage over time. Mercury also blocks the metabolic action of manganese and the entry of calcium ions into cytoplasm. Oxidative stress and reactive oxygen species (ROS) have also been implicated as major factors in neurological disorders including stroke, PD, Alzheimer’s, ALS, etc.

Programmed cell death (apoptosis) is documented to be a major factor in degenerative neurological conditions like ALS, Alzheimer’s, MS, Parkinson’s, etc. Some of the factors documented to be involved in apoptosis of neurons and immune cells include inducement of the inflammatory cytokine Tumor Necrosis Factor-alpha (TNFa), reactive oxygen species and oxidative stress, reduced glutathione levels, liver enzyme effects and inhibition of protein kinase C and cytochrome P450, nitric oxide and peroxynitrite toxicity, excitotoxicity and lipid peroxidation, excess free cysteine levels, excess glutamate toxicity, excess dopamine toxicity, beta-amyloid generation, increased calcium influx toxicity and DNA fragmentation and mitochondrial membrane dysfunction. The mechanisms by which mercury causes all of these conditions and neuronal apoptosis are documented in this review (often synergistically along with other toxic exposures).

Chronic neurological conditions such as Alzheimer’s appear to be primarily caused by chronic or acute brain inflammation. The brain is very sensitive to inflammation. Disturbances in metabolic networks: e.g. immuno-inflammatory processes, insulin-glucose homeostasis, adipokine synthesis and secretion, intra-cellular signaling cascades, and mitochondrial respiration have been shown to be major factors in chronic neurological conditions. Inflammatory chemicals such as mercury, aluminum, and other toxic metals as well as other excitotoxins including MSG and aspartame cause high levels of free radicals, lipid peroxidation, inflammatory cytokines, and oxidative stress in the brain and cardiovascular systems. Acetylcholine depletion has been found to be a major factor in Alzheimer’s, and aluminum has been found to inhibit choline transport and reduce neuronal choline acetyltransferase, which can lead to acetylcholine deficiency.

The brain has elaborate protective mechanisms for regulating neurotransmitters such as glutamate, which is the most abundant of all neurotransmitters. When these protective regulatory mechanisms are damaged or affected, chronic neurological conditions such as Alzheimer’s can result. Mercury and other toxic metals inhibit astrocyte function in the brain and CNS, causing increased glutamate and calcium related neurotoxicity. Mercury and increased glutamate activate free radical forming processes like xanthine oxidase which produce oxygen radicals and oxidative neurological damage. Nitric oxide related toxicity caused by peroxynitrite formed by the reaction of NO with superoxide anions, which results in nitration of tyrosine residues in neurofilaments and manganese Superoxide Dimustase (SOD) has been found to cause inhibition of the mitochondrial respiratory chain, inhibition of the glutamate transporter, and glutamate-induced neurotoxicity involved in ALS.

These inflammatory processes damage cell structures including DNA, mitochondria, and cell membranes. They also activate microglia cells in the brain, which control brain inflammation and immunity. Once activated, the microglia secrete large amounts of neurotoxic substances such as glutamate, an excitotoxin, which adds to inflammation and stimulates the area of the brain associated with anxiety. Inflammation also disrupts brain neurotransmitters resulting in reduced levels of serotonin, dopamine, and norepinephrine. Some of the main causes of such disturbances that have been documented include vaccines, mercury, aluminum, other toxic metals, MSG, aspartame, etc.

Programmed cell death (apoptosis) is documented to be a major factor in degenerative neurological conditions like ALS, Alzheimer’s, MS, Parkinson’s, etc. Some of the factors documented to be involved in apoptosis of neurons and immune cells include mitochondrial membrane dysfunction. Mitochondrial DNA mutations or dysfunction is fairly common, found in at least 1 in every 200 people, and toxicity effects affect this population more than those with less susceptibility to mitochondrial dysfunction. Mercury depletes GSH and damages cellular mitochrondria, which along with the increased lipid peroxidation in protein and DNA oxidation in the brain appears to be major factors in conditions such as autism, Parkinson’s disease, Alzheimer’s, etc. Some prevention and repair of such damage to mitochondria has been documented using pyroquinoline quinine (PQQ).

Reduced levels of magnesium and zinc are related to metabolic syndrome, insulin resistance, and brain inflammation and are protective against these conditions. Mercury and cadmium inhibiting magnesium and zinc levels as well as inhibiting glucose transfer are other mechanisms by which mercury and toxic metals are factors in metabolic syndrome and insulin resistance/diabetes.

TNFa (tumor necrosis factor-alpha) is a cytokine that controls a wide range of immune cell response in mammals, including cell death (apoptosis) in neuronal and immune cells. This process is involved in inflammatory and degenerative neurological conditions like ALS, MS, Parkinson’s, rheumatoid arthritis, etc. Cell signaling mechanisms like sphingolipids are part of the control mechanism for the TNFa apoptosis mechanism. Glutathione is an amino acid that is a normal cellular mechanism for controlling apoptosis. When glutathione is depleted in the brain, reactive oxidative species increased, and CNS and cell signaling mechanisms are disrupted by toxic exposures such as mercury, neuronal cell apoptosis results and neurological damage. Mercury has been shown to induce TNFa and deplete glutathione, causing inflammatory effects and cellular apoptosis in neuronal and immune cells.

Mercury’s biochemical damage at the cellular level include DNA damage, inhibition of DNA and RNA synthesis; alteration of protein structure; alteration of the transport of calcium; inhibition of glucose transport, and of enzyme function, protein transport, and other essential nutrient transport; induction of free radical formation, depletion of cellular glutathione (necessary for detoxification processes), inhibition of glutathione peroxidase enzyme, inhibits glutamate uptake, induces peroxynitrite and lipid peroxidation damage, causes abnormal migration of neurons in the cerebral cortex, immune system damage; and inducement of inflammatory cytokines. Homocysteine has been found to facilitate and increase mercury toxicity.

Na(+), K(+)-ATPase is a transmembrane protein that transports sodium and potassium ions across cell membranes during an activity cycle that uses the energy released by ATP hydrolysis. Mercury is documented to inhibit Na(+),K(+)-ATPase function at very low levels of exposure. Studies have found that in Alzheimer’s cases there was a reduction in serum magnesium and RBC membrane Na(+)-K+ ATPase activity and an elevation in plasma serum digoxin. The activity of all serum free-radical scavenging enzymes, concentration of glutathione, alpha tocopherol, iron binding capacity, and ceruloplasmin decreased significantly in Alzheimer’s, while the concentration of serum lipid peroxidation products and nitric oxide increased. The inhibition of Na+-K+ ATPase can contribute to increase in intracellular calcium and decrease in magnesium, which can result in 1) defective neurotransmitter transport mechanism, 2) neuronal degeneration and apoptosis, 3) mitochondrial dysfunction, and 4) defective golgi body function and protein processing dysfunction. It is documented in this paper that mercury is a cause of most of these conditions seen in Alzheimer’s.

Autoimmunity has also been found to be a factor in chronic degenerative autoimmune conditions such as ALS, with genetic susceptibility a major factor in who is affected. One genetic factor in Hg induced autoimmunity is major histocompatibility complex (MHC) linked. Both immune cell types Th1 and Th2 cytokine responses are involved in autoimmunity. One genetic difference found in animals and humans is cellular retention differences for metals related to the ability to excrete mercury. For example it has been found that individuals with genetic blood factor type APOE-4 do not excrete mercury readily and bio-accumulate mercury, resulting in susceptibility to chronic autoimmune conditions such as Alzheimer’s, Parkinson’s, etc. as early as age
40, whereas those with type APOE-2 readily excrete mercury and are less susceptible. Those with type APOE-3 are intermediate to the other 2 types. The incidence of autoimmune conditions has increased to the extent this is now one of the leading causes of death among women. Also when a condition has been initiated and exposure levels decline, autoimmune antibodies also decline in animals or humans.

Mercury has been found in autopsy studies to accumulate in the brain of those with chronic exposures, and levels are directly proportional to the number of amalgam filling surfaces. Dozens of studies have documented that exposure to inorganic mercury causes memory loss and memory problems. Mercury has been found to cause memory loss by inactivating enzymes necessary for brain cell energy production and proper assembly of the protein tubulin into microtubules. In a recent study, mercury at extremely low levels found commonly in those with amalgam fillings was found to disrupt membrane structure and linear growth rates of neurites in most nerve growth cones exposed, causing tubulin/microtubule structure to disintegrate. The study also found that mercury also interferes with formation of tubulin producing neurofibrillary tangles in the brain similar to those observed in Alzheimer’s patients, as well as causing neuronal somata to fail to sprout. The process was found to result in low levels of zinc in the brain. There is evidence that certain redox active metal ions including copper and mercury are important in exacerbating and perhaps facilitating Abeta-mediated oxidative damage and amyloid deposits in Alzheimer’s disease.

Mercury has also been shown to induce cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in neuroblastoma cells resulting in amyloid plaques which is found in Alzheimer’s patients, and to also cause the formation of the neurofibrilla tangles found in the Alzheimer’s patient brain. Mercury and the induced neurofibrillary tangles also appear to produce a functional zinc deficiency in AD sufferers, as well as causing reduced lithium levels which is another factor in such diseases. Lithium protects brain cells against excess glutamate induced excitability and calcium influx. These studies clearly implicate mercury as having the ability to cause neurodegeneration in the brain and CNS, at levels of 20 ppb, which is lower than that of many with several amalgam fillings or dental occupational exposure. Researchers at Geriatric and Psychiatric Univ. Clinics in Basel, Switzerland concluded that inorganic mercury appears to be a causative factor in Alzheimer’s, and the Swiss Dental Assoc. recommended avoidance of amalgam use in those with neurological disorders.

Clinical experience has also found that DMSO has some ability to repair tubulin damage. Clinical tests of patients with MND, ALS, Parkinson’s, Alzheimer’s, Lupus (SLE), rheumatoid arthritis and autism have found that the patients generally have elevated plasma cysteine to sulfate ratios, with the average being 500% higher than controls, and in general being poor sulfur oxidizers. This means that these patients have insufficient sulfates available to carry out necessary bodily processes and that cysteine levels build up in the brain and CNS to neurotoxic levels. Mercury has been shown to diminish and block sulfur oxidation and thus reducing glutathione levels which is the part of this process involved in detoxifying and excretion of toxics like mercury. Glutathione is produced through the sulfur oxidation side of this process. Low levels of available glutathione have been shown to increase mercury retention and increase toxic effects, while high levels of free cysteine have been demonstrated to make toxicity due to inorganic mercury more severe. Mercury has also been found to play a part in inducing intolerance and neuronal problems through blockage of the P-450 enzymatic process.

Mercury also blocks the immune function of magnesium and zinc, whose deficiencies are known to cause significant neurological effects. The low Zn levels result in deficient CuZnSuperoxide dismutase (CuZnSOD), which in turn leads to increased levels of superoxide due to toxic metal exposure. Mercury is known to damage or inhibit SOD activity. Mercury induced lipid peroxidation has been found to be a major factor in mercury’s neurotoxicity, along with leading to decreased levels of glutathione peroxidation and superoxide dismutase (SOD).

Mercury inhibits sulfur ligands in MT and in the case of intestinal cell membranes inactivates MT that normally bind cuprous ions, thus allowing buildup of copper to toxic levels in many and malfunction of the Zn/Cu SOD function. Modern amalgams commonly used in the U.S. have higher levels of copper than the traditional silver amalgams and result in much higher exposure levels to mercury and copper. This is a factor in higher incidence of neurodegenerative conditions like Alzheimer’s. Exposure to mercury results in changes in metalloprotein compounds that have genetic effects, having both structural and catalytic effects on gene expression. Some of the processes affected by such MT control of genes include cellular respiration, metabolism, enzymatic processes, metal-specific homeostasis, and adrenal stress response systems. Significant physiological changes occur when metal ion concentrations exceed threshold levels.

Copper is an essential trace metal which plays a fundamental role in the biochemistry of the nervous system. Several chronic neurological conditions involving copper metabolic disorders are well documented like Wilson’s Disease and Menkes Disease. Mutations in the copper/zinc enzyme superoxide dismutase (SOD) have been shown to be a major factor in the motor neuron degeneration in conditions like familial ALS and similar effects on Cu/Zn SOD to be a factor in other conditions such as autism, Alzheimer’s, Parkinson’s, and non-familial ALS. This condition can result in zinc deficient SOD and oxidative damage involving nitric oxide, peroxynitrite, and lipid peroxidation, which have been found to affect glutamate mediated excitability and apoptosis of nerve cells and effects on mitochondria. These effects can be reduced by zinc supplementation, as well as supplementation with antioxidants and nitric oxide-suppressing agents and peroxynitrite scavengers such as Vit C, Vit E, lipoic acid, Coenzyme Q10, carnosine, gingko biloba, N-acetylcysteine, turmeric, etc. Some of the antioxidants were also found to have protective effects through increasing catalase and SOD action, while reducing lipid peroxidations. Curcumin as an antioxidant, anti-inflammatory and lipophilic action improves the cognitive functions in patients with AD. A growing body of evidence indicates that oxidative stress, free radicals, beta amyloid, cerebral deregulation caused by bio-metal toxicity and abnormal inflammatory reactions contribute to the key event in Alzheimer’s disease pathology. Due to various effects of curcumin, such as decreased Beta-amyloid plaques, delayed degradation of neurons, metal-chelation, anti-inflammatory, antioxidant and decreased microglia formation, the overall memory in patients with AD has improved. Ceruloplasmin in plasma can be similarly affected by copper metabolism dysfunction, like SOD function, and is often a factor in neurodegeneration.

Studies showed that metals can induce A-beta aggregation and toxicity and are concentrated in Alzheimer’s brain. There is accumulating evidence that interactions between beta-amyloid and copper, iron, and zinc are associated with the pathophysiology of Alzheimer’s disease (AD). A significant dyshomeostasis of copper, iron, and zinc has been detected, and the mismanagement of these metals induces beta-amyloid precipitation and neurotoxicity. Chelating agents offer a potential therapeutic solution to the neurotoxicity induced by copper and iron dyshomeostasis. Currently, the copper and zinc chelating agents clioquinol and desferroxamine represent a potential therapeutic route that may not only inhibit beta-amyloid neurotoxicity, but may also reverse the accumulation of neocortical beta-amyloid. There is also evidence that melatonin and curcumin may have beneficial effects on reducing metal toxic. Turmeric/curcumin has been found to reduce some of the toxic and inflammatory effects of toxic metals.

Low levels of mercury and toxic metals have been found to inhibit dihydroteridine reductase, which affects the neural system function by inhibiting transmitters through its effect on phenylalanine, tyrosine and tryptophan transport into neurons. This was found to cause severe impaired amine synthesis and hypokinesis. Tetrahydrobiopterin, which is essential in production of neurotransmitters, is significantly decreased in patients with Alzheimer’s, Parkinson’s, MS, and autism. Such patients have abnormal inhibition of neurotransmitter production.

Some studies have also found persons with chronic exposure to electromagnetic fields (EMF) to have higher levels of mercury exposure and excretion. Magnetic fields are known to induce current in metals and would increase the effects of galvanism. Occupational exposure to higher levels of EMF have also been found in many studies to result in much higher risk of chronic degenerative neurological conditions such as ALS and Alzheimer’s Disease. Since EMF causes increased mercury exposure in those with amalgam, and mercury is also known to cause these conditions, again it is not clear the relative importance of the factors since the studies were not controlled for mercury levels or number of amalgam fillings.

Studies have also found a correlation between high levels of aluminum exposure and dementia such as Alzheimer’s, and concluded based on extensive literature that the neurotoxic effects of aluminum are beyond any doubt, and aluminum as a factor in some AD cannot be discarded. It is well documented that neurological effects of toxics are synergistic. Flu shots have mercury and aluminum which both are known to accumulate in the brain over time. A study of people who received flu shots regularly found that if an individual had five consecutive flu shots between 1970 and 1980 (the years studied) his/her chances of getting Alzheimer’s Disease is ten times higher than if they had one or no shots.

Many studies of patients with major neurological or degenerative diseases have found evidence amalgam fillings may play a major role in development of conditions such as such as Alzheimer’s and significantly improve after dental amalgam replacement and dental infection cleanup. Low levels of toxic metals have been found to inhibit dihydroteridine reductase, which affects the neural system function by inhibiting brain transmitters through its effect on phenylalanine, tyrosine and tryptophan transport into neurons. This was found to cause severe impaired amine synthesis and hypokinesis. Tetrahydro biopterin, which is essential in production of neurotransmitters, is significantly decreased in patients with Alzheimer’s, Parkinson’s, and MS. Such patients have abnormal inhibition of neurotransmitter production. (Supplements which inhibit breach of the blood brain barrier such as bioflavonoids have been found to slow such neurological damage).

Also mercury binds with cell membranes interfering with sodium and potassium enzyme functions, causing excess membrane permeability, especially in terms of the blood-brain barrier. Less than 1ppm mercury in the blood stream can impair the blood- brain barrier. Mercury was also found to accumulate in the mitochondria and interfere with their vital functions, and to inhibit cytochrome C enzymes which affect energy supply to the brain. Persons with the APO-E4 gene form of apolipoprotein E which transports cholesterol in the blood, are especially susceptible to this damage, while those with APO-E2 which has extra cysteine and is a better mercury scavenger have less damage. The majority have an intermediate form APO-E3. This appears to be a factor in susceptibility to Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. One’s susceptibility can be estimated by testing for this condition. Repeated exposure to pesticides has also been found to increase Alzheimer’s disease risk.

A major systematic review of all medical studies found on the connection of mercury exposure and Alzheimer’s disease was recently carried out by MDs and PhDs. Studies were screened according to a pre-defined protocol. The author’s noted that mercury is one of the most toxic substances known to humans and in addition to being widespread in the environment has also been used extensively in vaccinations and dental amalgam. Studies were screened according to a pre-defined protocol. Most of the studies testing memory in individuals exposed to inorganic mercury (IM) found significant memory deficits. Some autopsy studies found increased mercury levels in brain tissues of AD patients.

In vitro models showed that IM reproduces all pathological changes seen in AD, and in animal models IM produced changes that are similar to those seen in AD. Its high affinity for selenium and selenoproteins suggests that IM may promote neurodegenerative disorders via disruption of redox regulation. IM appears to play a role as a co-factor in the development of AD. It appears to also increase the pathological influence of other metals through adverse effects on the blood brain barrier. Our mechanistic model describes potential causal pathways. It concludes: As the single most effective public health primary preventive measure, industrial, and medical usage of mercury should be eliminated as quickly as possible.

Earlier research on the biochemical abnormalities of the Alzheimer’s disease (AD) brain showed that mercury, and only mercury, at very low levels induced the same biochemical abnormalities when added to normal human brain homogenates or in the brains of rats exposed to mercury vapor. Since the brain is more vulnerable to oxidative stress than any other organ, it is not surprising that mercury, which promotes oxidative stress, is an important risk factor for brain disorders.

Insulin Resistance as a Factor in Alzheimer’s Disease

Higher insulin and glucose levels in the blood and deficiency of glucose in brain cells that need it has been found to lead to neurological problems such as Alzheimer’s. Those with either type I or type II diabetes have been found to be more likely to have other chronic conditions including heart disease, strokes, kidney disease, Alzheimer’s, eye conditions and blindness. Diabetes also impacts memory by increasing the risk blood vessels will become obstructed, restricting blood flow to the brain. High blood glucose levels also impact cognition through formation of sugar-related toxins called advanced glycation end products (AGEs). AGEs have been found to be a factor in aging, diabetes, and Alzheimer’s. Glycotoxins are formed when sugars interact with proteins and lipids, damaging the structure of proteins and membranes, rendering them less able to carry out their many vital processes. Studies have shown that AGEs are a key factor in cross-linking of harmful beta-amyloid plaques in the brain that are implicated in Alzheimer’s. As previously documented mercury and aluminum exposure increase insulin resistance and amalgam replacement and detoxification reduce insulin resistance.

Inflammation induced by vaccine adjuvants like aluminum and mercury or by excitotoxins like MSG has been found to play a significant role in insulin resistance (type-2 diabetes) and in high levels of LDL cholesterol. Reduced levels of magnesium and zinc are related to metabolic syndrome, insulin resistance, and brain inflammation, and these are protective against these conditions. Mercury and cadmium by inhibiting magnesium and zinc levels as well as inhibiting glucose transfer are other mechanisms by which mercury and toxic metals are factors in metabolic syndrome and insulin resistance/diabetes. Mercury inhibits production of insulin and is a factor in diabetes and hypoglycemia, with significant reductions in insulin need after replacement of amalgam fillings and normalizing of blood sugar. Iron overload has also been found to be a cause of insulin resistance/type 2 diabetes.

Treatment of Alzheimer’s

In some cases replacement of amalgam fillings or toxic metals chelation has been found to result in cure or significant improvement in Alzheimer’s patients. Alzheimer’s patients commonly are found to be deficient in omega 3 fatty acids, vit C, B12, SAMe, vit K, etc. and clinical experience has found supplementing these to be beneficial in some cases. A study demonstrated protective effects of methylcobalamin, a vitamin B12 analog, against glutamate-induced neurotoxicity, and similarly for iron in those who are iron deficient. Supplements with clinical experience indicating benefit in many Alzheimer’s/dementia cases include pantothenic acid(B5), vit B12, vit B1, vit B6, Vit E, Ginkgo Biloba, Vit C, Acetyl-L-Carnatine, CoQ10, EFAs(DHA/EPA), N-Acetyl-Cysteine(NAC), SAMe, folate, inositol, melatonin, carnosine. Two treatments shown to be significantly beneficial in the majority of Alzheimer’s patients using the supplement are Huperzine A and Kami-Umtan-To (KUT). Lithium supplements (lithium carbonate and lithium oratate) have been found to be effective in protecting neurons and brain function from oxidative and excitotoxic effects. A recent study demonstrated that combined treatment with lithium and valproic acid elicits synergistic neuroprotective effects against glutamate excitotoxicity in cultured brain neurons.

References

  1. Hussain S, et al. Mercuric chloride-induced reactive oxygen species and its effect on antioxidant enzymes in different regions of rat brain. J Environ Sci Health B. 1997; 32(3): 395-409.
  2. Bulat P. Activity of Gpx and SOD in workers occupationally exposed to mercury. Arch Occup Environ Health. 1998; 71: S37-9.
  3. Stohs SJ, Bagchi D. Oxidative mechanisms in the toxicity of metal ions. Free Radic Biol Med. 1995; 18(2): 321-36.
  4. Jay D. Glutathione inhibits SOD activity of Hg. Arch Inst Cardiol Mex. 1998; 68(6): 457-61.
  5. Tan S, et al. Oxidative stress induces programmed cell death in neuronal cells. J Neurochem. 1998; 71(1): 95-105.
  6. Matsuda T, Takuma K, Lee E, et al. Apoptosis of astroglial cells. Nippon Yakurigaku Zasshi. 1998; 112(1): 24.
  7. Lee YW, Ha MS, Kim YK. Role of reactive oxygen species and glutathione in inorganic mercury-induced injury in human glioma cells. Neurochem Res. 2001; 26(11): 1187-93.
  8. Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: Glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res. 2002 Dec 1; 70(5): 694-702.
  9. Bridges CC. Homocysteine, system b0,+ and the renal epithelial transport and toxicity of inorganic mercury. Am J Pathol. 2004; 165(4): 1385-94.
  10. Vimy MJ, Takahashi Y, Lorscheider FL. Maternal-fetal distribution of mercury released from dental amalgam fillings. Amer J Physiol. 1990; 258: R939-945.
  11. Boyd ND, Vimy J, et al. Mercury from dental “silver” tooth fillings impairs sheep kidney function. Am J Physiol. 1991; 261(30): R1010-R1014.
  12. Hahn L, et al. Distribution of mercury released from amalgam fillings into monkey tissues. FASEB J. 1990; 4: 5536.
  13. Galic N, Ferencic Z, et al. Dental amalgam mercury exposure in rats. Biometals. 1999; 12(3): 227-31.
  14. Markovich, et al, Heavy metals (Hg,Cd) inhibit the activity of the liver and kidney sulfate transporter Sat-1. Toxicol Appl Pharmacol. 1999; 154(2): 181-7.
  15. McFadden SA. Xenobiotic metabolism and adverse environmental response: Sulfur-dependent detox pathways. Toxicology. 1996; 111(1-3): 43-65.
  16. Langley-Evans SC, et al. SO2: A potent glutathione depleting agent. Comp Biochem Physiol Pharmocol Toxicol Endocrinol. 1999; 114(2): 89-98.
  17. Alberti A, Pirrone P, Elia M, Waring RH, Romano C. Sulphation deficit in “low-functioning” autistic children. Biol Psychiatry. 1999; 46(3): 420-4.
  18. Huggins HA, Levy TE. Uniformed Consent: The Hidden Dangers in Dental Care. Hampton Roads Publishing Company; 1999.
  19. Huggins H. It’s All in Your Head. Bio-Probe; 1997.
  20. Schmidt F. et al. Mercury in urine of employees exposed to magnetic fields. Tidsskr Nor Laegeforen. 1997; 117(2): 199-202.
  21. Sheppard AR, Eisenbud M. Biological Effects of Electric and Magnetic Fields of Extremely Low Frequency. New York University Press; 1977.
  22. Ortendahl T W, Hogstedt P, Holland RP. Mercury vapor release from dental amalgam in vitro caused by magnetic fields generated by CRT’s. Swed Dent J. 1991: 31.
  23. Omura, Yoshiaki. Abnormal Deposits of Al, Pb, and Hg in the brain, particularly in the hippocampus, as one of the main causes of decreased cerebral acetylcholine, electromagnetic field hypersensitivity, pre-Alzheimer’s disease, and autism in children. Acupuncture & Electro-Therapeutics Research. 2000; 25(3/4): 230.
  24. Savitz DA, Checkoway H, Loomis DP. Magnetic field exposure and neurodegenerative disease mortality among electric utility workers. Epidemiology. 1998; 9(4): 398-404.
  25. Savitz DA, Loomis DP, Tse CK. Electrical occupations and neurodegenerative disease: Analysis of U.S. mortality data. Arch Environ Health. 1998; 53(1): 71-4.
  26. Johansen C, Olsen JH. Mortality from amyotrophic lateral sclerosis, other chronic disorders, and electric shocks among utility workers. Am J Epidemiol. 1998; 148(4): 362-8.
  27. Davanipour Z, Sobel E, Bowman JD, Qian Z, Will AD. Amyotrophic lateral sclerosis and occupational exposure to electromagnetic fields. Bioelectromagnetics. 1997; 18(1): 28-35.
  28. Sobel E, Dunn M, Davanipour Z, Qian Z, Chui HC. Elevated risk of Alzheimer’s disease among workers with likely electromagnetic field exposure. Neurology. 1996; 47(6): 1477-81.
  29. Sobel E, Davanipour Z. Electromagnetic field exposure may cause increased production of amyloid beta and eventually lead to Alzheimer’s disease. Neurology. 1996; 47(6): 1594-600.
  30. Sobel E, Davanipour Z, Sulkava R, Erkinjuntti T, Wikstrom J, et al. Occupations with exposure to electromagnetic fields: a possible risk factor for Alzheimer’s disease. Am J Epidemiol. 1995; 142(5): 515-24.
  31. Babich, et al. The mediation of mutagenicity and clastogenicity of heavy metals by physiochemical factors. Environ Res. 1985: 37; 253-286.
  32. Hansen K, et al. A survey of metal induced mutagenicity in vitro and in vivo. J Amer Coll Toxicol. 1984: 3; 381-430.
  33. Rodgers JS, Hocker JR, et al. Mercuric ion inhibition of eukaryotic transcription factor binding to DNA. Biochem Pharmacol. 2001; 61(12): 1543-50.
  34. Knapp LT, Klann E. Superoxide-induced stimulation of protein kinase C via thiol modification and modulation of zinc content. J Biol Chem. 2000.
  35. Jenner P. Oxidative mechanisms in PD. Mov Disord. 1998; 13(1): 24-34.
  36. Offen D, et al. Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels. Neurology. 1998; 51(4): 1100-3.
  37. Rajanna B, et al. Modulation of protein kinase C by heavy metals. Toxicol Lett. 1995; 81(2-3): 197-203.
  38. Badou A, et al. HgCl2-induced IL-4 gene expression in T cells involves a protein kinase C-dependent calcium influx through L-type calcium channels. J Biol Chem. 1997; 272(51): 32411-8.
  39. Veprintsev DB. Pb2+ and Hg2+ binding to alpha-lactalbumin. Biochem Mol Biol Int. 1996; 39(6): 1255-65.
  40. Kingman A, et al. Mercury concentrations in urine and blood associated with amalgam exposure in the U.S. military population. Dent Res. 1998; 77(3): 461-71.
  41. Lund ME, et al. Treatment of acute MeHg poisoning by NAC. J Toxicol Clin Toxicol. 1984; 22(1): 31-49.
  42. Livardjani F, Ledig M, Kopp P, Dahlet M, Leroy M, Jaeger A. Lung and blood superoxide dismutase activity in mercury vapor exposed rats: Effect of N-acetylcysteine treatment. Toxicology. 1991; 66(3): 289-95.
  43. Balch JF, et al. Prescription for Nutritional Healing. 2nd ed. 1997.
  44. Nicole A, et al. Direct evidence for glutathione as mediator of apoptosis in neuronal cells. Biomed Pharmacother. 1998; 52(9): 349-55.
  45. Spencer JP, et al. Cysteine & GSH in PD: Mechanisms involving ROS. J Neurochem. 1998; 71(5): 2112-22.
  46. Bains JS, et al. Neurodegenerative disorders in humans and role of glutathione in oxidative stress mediated neuronal death. Brain Res Rev. 1997; 25(3): 335-58.
  47. Medina S, Martinez M, Hernanz A. Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1-42. Free Radic Res. 2002; 36(11): 1179-84.
  48. Offen D, et al. Use of thiols in treatment of PD. Exp Neurol. 1996; 141(1): 32-9.
  49. Pocernich CB, et al. Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: Relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem Int. 2001; 39(2): 141-9.
  50. Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson’s disease. J Neural Transm. 1997; 104(6-7): 661-77.
  51. Shen XM, et al. Neurobehavioral effects of NAC conjugates of dopamine: Possible relevance for Parkinson’s disease. Chem Res Toxicol. 1996; 9(7): 1117-26.
  52. Li H, Shen XM, Dryhurst G. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3, 4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson’s disease. J Neurochem. 1998; 71(5): 2049-62.
  53. Araragi S, Sato M. et al. Mercuric chloride induces apoptosis via mitochondrial-dependent pathway in human leukemia cells. Toxicology. 2003; 184(1): 1-9.
  54. Thompson CM, Markesbery WR, et al. Regional brain trace-element studies in Alzheimer’s disease. Neurotoxicology. 1998; 9(1): 1-7.
  55. Hock, et al. Increased blood mercury levels in Alzheimer’s patients. Neural Transm. 1998; 105: 59-68.
  56. Cornett, et al. Imbalances of trace elements related to oxidative damage in Alzheimer’s diseased brain. Neurotoxicolgy. 1998; 19: 339-345.
  57. Vance DE, Ehmann WD, Markesbery WR. A search for longitudinal variations in trace element levels in nails of Alzheimer’s disease patients. Biol Trace Elem Res. 1990; 26-27: 461-70.
  58. Bjorkman L, et al. Mercury in saliva and feces after removal of amalgam fillings. Toxicol App Pharm. 1997; 144(1): 156-62.
  59. Skare I, et al. Human exposure to Hg released from dental amalgam restorations. Archives of Environmental Health. 1994; 49(5): 384-394.
  60. Veltman JC, et al. Alterations of heme, cytochrome P-450, and steroid metabolism by mercury in rat adrenal gland. Arch Biochem Biophys. 1986; 248(2): 467-78.
  61. Riedl AG, et al. P450 and hemeoxygenase enzymes in the basal ganglia and their roles in Parkinson’s disease. Adv Neurol. 1999; 80: 271-86.
  62. Zamm AV. Dental mercury: A factor that aggravates and induces xenobiotic intolerance. J Orthmol Med. 1991; 6(2): 67-77.
  63. Weiner JA, et al. The relationship between mercury concentration in human organs and predictor variables. Sci Tot Environ. 1993; 138(1-3): 101-115.
  64. Nylander M, et al. Mercury concentrations in the human brain and kidneys and exposure from amalgam fillings. Swed Dent J. 1987; 11: 179-187.
  65. Eggleston DW, et al. Correlation of dental amalgam with mercury in brain tissue. J Prosthet Dent. 1987; 58(6): 704-7.
  66. Goyer RA. Toxic and essential metal interactions. Annu Rev Nutr. 1997; 17: 37-50.
  67. Goyer RA, et al. Environmental risk factors for osteoporosis. Envir Health Perspectives. 1994; 102(4): 390-394.
  68. Lindh U, Carlmark B, Gronquist SO, Lindvall A. Metal exposure from amalgam alters the distribution of trace elements in blood cells and plasma. Clin Chem Lab Med. 2001; 39(2): 134-142.
  69. Goldberg AF, et al. Effect of amalgam restorations on whole body potassium and bone mineral content in older men. Gen Dent. 1996; 44(3): 246-8.
  70. Schirrmacher K. Effects of lead, mercury, and methyl mercury on gap junctions and [Ca2+]I in bone cells. Calcif Tissue Int. 1998; 63(2): 134-9.
  71. Quig D. Cysteine metabolism and metal toxicity. Altern Med Rev. 1998; 3(4): 262-270.
  72. de Ceaurriz J, et al. Role of gamma-glutamyltraspeptidase(GGC) and extracellular glutathione in dissipation of inorganic mercury. J Appl Toxicol. 1994; 14(3): 201.
  73. Berndt WO, et al. Renal glutathione and mercury uptake. Fundam Appl Toxicol. 1985; 5(5): 832-9.
  74. Zalups RK, Barfuss DW. Accumulation and handling of inorganic mercury in the kidney after co-administration with glutathione. J Toxicol Environ Health. 1995; 44(4): 385-99.
  75. Clarkson TW, et al. Billiary secretion of glutathione-metal complexes. Fundam Appl Toxicol. 1985; 5(5): 816-31.
  76. Aschner M, et al. Metallothionein induction in fetal rat brain by in utero exposure to elemental mercury vapor. Brain Research. 1997; 778(1): 222-32.
  77. Aschner M, Rising L, Mullaney KJ. Differential sensitivity of neonatal rat astrocyte cultures to mercuric chloride (MC) and methylmercury (MeHg): Studies on K+ and amino acid transport and metallothionein (MT) induction. Neurotoxicology. 1996; 17(1): 107-16.
  78. O’Halloran TV. Transition metals in control of gene expression. Science. 1993; 261(5122): 715-25.
  79. Matts RL, Schatz JR, Hurst R, Kagen R. Toxic heavy metal ions inhibit reduction of disulfide bonds. J Biol Chem. 1991; 266(19): 12695-702.
  80. Boot JH. Effects of SH-blocking compounds on the energy metabolism in isolated rat hepatocytes. Cell Struct Funct. 1995; 20(3): 233-8.
  81. Baauweegers HG, Troost D. Localization of metallothionein in the mammilian central nervous system. Biol Signals. 1994; 3: 181-7.
  82. Ronnback L, et al. Chronic encephalopaties induced by low doses of mercury or lead. Br J Ind Med. 1992; 49: 233-240.
  83. Langauer-Lewowicka H. Changes in the nervous system due to occupational metallic mercury poisoning. Neurol Neurochir Pol. 1997; 31(5): 905-13.
  84. Langauer-Lewowicka H. Chronic toxic encephalopathies. Med Pr. 1982; 33(1-3): 113-7.
  85. Ono B, et al, Reduced tyrosine uptake in strains sensitive to inorganic mercury. Genet. 1987; 11(5): 399.
  86. Singh I, Pahan K, Khan M, Singh AK. Cytokine-mediated induction of ceramide production is redox-sensitive. Implications to pro-inflammatory cytokine-mediated apoptosis in demyelinating diseases. J Biol Chem. 1998; 273(32): 20354-62.
  87. Pahan K, Raymond JR, Singh I. Inhibition of phosphatidylinositol 3-kinase induces nitric-oxide synthase in lipopolysaccharide- or cytokine-stimulated C6 glial cells. J Biol Chem. 1999; 274: 7528-7536.
  88. Xu J, Yeh CH, et al, Involvement of de novo ceramide biosynthesis in tumor necrosis factor-alpha/cycloheximide-induced cerebral endothelial cell death. J Biol Chem. 1998; 273(26): 16521-6.
  89. Dbaibo GS, El-Assaad W, et al. Ceramide generation by two distinct pathways in tumor necrosis factor alpha-induced cell death. FEBS Lett. 2001; 503(1): 7-12.
  90. Liu B, Hannun YA, et al. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J Biol Chem. 1998; 273(18): 11313-20.
  91. Noda M, Wataha JC, et al, Sublethal, 2-week exposures of dental material components alter TNF-alpha secretion of THP-1 monocytes. Dent Mater. 2003; 19(2): 101-5.
  92. Kim SH, Johnson VJ, Sharma RP. Mercury inhibits nitric oxide production but activates proinflammatory cytokine expression in murine macrophage: differential modulation of NF-kappaB and p38 MAPK signaling pathways. Nitric Oxide. 2002; 7(1): 67-74.
  93. Dastych J, Metcalfe DD, et al. Murine mast cells exposed to mercuric chloride release granule-associated N-acetyl-beta-D-hexosaminidase and secrete IL-4 and TNF-alpha. J Allergy Clin Immunol. 1999; 103(6): 1108-14.
  94. Tortarolo M, Veglianese P, et al. Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol Cell Neurosci. 2003; 23(2): 180-92.
  95. Haley BE. The relationship of the toxic effects of mercury to exacerbation of the medical condition classified as Alzheimer’s disease. Medical Veritas. 2007: 1510–1524.
  96. Lorscheider FL, Haley BE, et al. Mercury vapor inhibits tubulin binding. FASEB J. 1995; 9(4): A-3485.
  97. Wenstrup, et al. Trace element imbalances in the brains of Alzheimer’s patients. Research. 1990; 533: 125-131.
  98. de Saint-Georges, et al. Inhibition by mercuric chloride of the in vitro polymeriztion of microtubules. CR Seances Soc Biol Fil. 1984; 178(5): 562-6.
  99. Basun H, et al. Metals in plasma and cerebrospinal fluid in normal aging and Alzheimer’s disease. J Neural Transm Park Dis Dement Sect. 1991; 3(4): 231-58.
  100. Ngim CH, et al. Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson’s disease. Neuroepidemiology. 1989; 8(3): 128-41.
  101. Willershausen B, et al. Mercury in the mouth mucosa of patients with amalgam fillings. Dtsch Med Wochenschr. 1992; 117(46): 1743-7.
  102. Mathieson PW. Mercury: god of TH2 cells. Clinical Exp Immunol. 1995; 102(2): 229-30.
  103. Heo Y, Parsons PJ, Lawrence DA, Lead differentially modifies cytokine production in vitro and in vivo. Toxicol Appl Pharmacol. 1996; 138: 149-57.
  104. Nogi N. Electric current around dental metals as a factor producing allergic metal ions in the oral cavity. Nippon Hifuka Gakkai Zasshi. 1989; 99(12): 1243-54.
  105. Bergdahl J, Certosimo AJ, et al. Oral Electricity. Gen Dent. 1996; 44(4): 324-6.
  106. Ogletree RH, et al. Effect of mercury on corrosion of eta’ Cu-Sn phase in dental amalgams. Dent Mater. 1995; 11(5): 332-6.
  107. Meyer RD, et al. Intraoral galvanic corrosion. Prosthet Dent. 1993; 69(2): 141-3.
  108. Owens BM, et al. Localized galvanic shock after insertion of an amalgam restoration. Compenium. 1993; 14(10): 1302, 1304, 1306-7.
  109. Zalups RK, et al. Nephrotoxicity of inorganic mercury co-administered with L-cysteine. Toxicology. 1996; 109(1): 15-29.
  110. Perry TL, et al. Hallevorden-Spatz disease: Cysteine accumulation and cysteine dioxygenase deficiency. Ann Neural. 1985; 18(4): 482-489.
  111. Fabbri E, Caselli F, Piano A, Sartor G, Capuzzo A. Cd2+ and Hg2+ affect glucose release and cAMP-dependent transduction pathway in isolated eel hepatocytes. Aquat Toxicol. 2003; 62(1): 55-65.
  112. Bapu C, Purohit RC, Sood PP. Fluctuation of trace elements during methylmercury toxication and chelation therapy. Hum Exp Toxicol. 1994; 13(12): 815-23.
  113. West ES, et al. Textbook of Biochemistry. MacMillan Co; 1957: 853.
  114. Danielsson BRG, et al. Ferotoxicity of inorganic mercury: Distribution and effects of nutrient uptake by placenta and fetus. Biol Res Preg Perinatal. 1984; 5(3): 102-109.
  115. Warren T. Beating Alzheimer’s. Avery Publishing Group; 1991.
  116. Palkiewicz P, Zwiers H, Lorscheider FL. ADP-Ribosylation of brain neuronal proteins is altered by in vitro and in vivo exposure to inorganic mercury. Journal of Neurochemistry. 1994; 62(5): 2049-2052.
  117. Golden R, et al. Dementia and Alzheimer’s disease. Minnesota Medicine. 1995; 78: 25-29.
  118. Schofield P. Dementia associated with toxic causes and autoimmune disease. Int Psychogeriatr. 2005; 17(1): S129-47.
  119. Klock B, Blomgren J, Ripa U, Andrup B. Effekt av amalgamavlägsnande på patienter som misstänker att de lider eller har lidit av amalgamförgiftning. Tandläkartidn. 1989; 81(23): 1297-1302.
  120. Bigazzi PE. Autoimmunity and heavy metals. Lupus. 1994; 3: 449-453.
  121. Pollard KM, Pearson Dl, Hultman P. Lupus-prone mice as model to study xenobiotic-induced autoimmunity. Environ Health Perspect. 1999; 107(5): 729-735.
  122. Nielsen JB; Hultman P. Experimental studies on genetically determined susceptibility to mercury-induced autoimmune response. Ren Fail. 1999; 21(3-4): 343-8.
  123. Hultman P, Enestrom S. Mercury induced antinuclear antibodies in mice. Clinical and Exper Immunology. 1988; 71(2): 269-274.
  124. Constantinidis J, et al. Hypothesis regarding amyloid and zinc in the pathogenisis of Alzheimer’s disease. Alzheimer Dis Assoc Disord. 1995; 5(1): 31-35.
  125. Bjorklund G. Can mercury cause Alzheimer’s? Tidsskr Nor Laegeforen. 1991.
  126. Basun H, et al. Trace metals in plasma and cerebrospinal fluid in Alzheimer’s disease. J Neural Transm Park Dis Dement Sect. 1991; 3(4): 231.
  127. Smith, et al. Pteridines and mono-amines: Relevance to neurological damage. Postgrad Med J. 1986; 62(724): 113-123.
  128. Kay AD, et al. Cerebrospinal fluid biopterin is decreased in Alzheimer’s disease. Arch Neurol. 1986; 43(10): 996-9.
  129. Yamiguchi T, et al. Effects of tyrosine administration on serum bipterin in patients with Parkinson’s Disease and normal controls. Science. 1983; 219(4580): 75-77.
  130. Nagatsu T, et al. Catecholoamine-related enzymes and the biopterin cofactor in Parkinson’s. Neurol. 1984; 40: 467-73.
  131. Ely JTA. Mercury induced Alzheimer’s disease: Accelerating incidence? Bull Environ Contam Toxicol. 2001; 67: 800-6.
  132. Woods JS, et al. Urinary porphyrin profiles as biomarker of mercury exposure: Studies on dentists. J Toxicol Environ Health. 1993; 40(2-3): 235.
  133. Woods JS. Altered porphyrin metabolites as a biomarker of mercury exposure and toxicity. Physiol Pharmocol. 1996; 74(2): 210-15.
  134. Martin MD, et al. Validity of urine samples for low-level mercury exposure assessment and relationship to porphyrin and creatinine excretion rates. J Pharmacol Exp Ther. 1996.
  135. Woods JS. et al. Effects of porphyrinogenic metals on coproporphrinogen oxidase in liver and kidney. Toxicol App Pharmacol. 1989; 97: 183-190.
  136. Strubelt O, Kremer J, et al. Comparative studies on the toxicity of mercury, cadmium, and copper toward the isolated perfused rat liver. J Toxicol Environ Health. 1996; 47(3): 267-83.
  137. Kaliman PA, Nikitchenko IV, Sokol OA, Strel’chenko EV. Regulation of heme oxygenase activity in rat liver during oxidative stress induced by cobalt chloride and mercury chloride. Biochemistry (Mosc). 2001; 66(1): 77-82.
  138. Kumar SV, Maitra S, Bhattacharya S. In vitro binding of inorganic mercury to the plasma membrane of rat platelet affects Na+-K+-Atpase activity and platelet aggregation. Biometals. 2002; 15(1): 51-7.
  139. Kumar AR, Kurup PA. Inhibition of membrane Na+-K+ ATPase activity: A common pathway in central nervous system disorders. J Assoc Physicians India. 2002; 50: 400-6.
  140. Kurup RK, Kurup PA. Hypothalamic digoxin, hemispheric chemical dominance, and Alzheimer’s disease. Int J Neurosci. 2003; 113(3): 361-81.
  141. Nonaka S, et al. Lithium treatment protects neurons in CNS from glutamate induced excitability and calcium influx. Neurobiology. 1998; 95(5): 2642-2647.
  142. Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience. 2008; 155(3): 567-72.
  143. Hisatome I, Kurata Y, et al. Block of sodium channels by divalent mercury: role of specific cysteinyl residues in the P-loop region. Biophys J. 2000; 79(3): 1336-45.
  144. Bhattacharya S, Sen S, et al. Specific binding of inorganic mercury to Na(+)-K(+)-ATPase in rat liver plasma membrane and signal transduction. Biometals. 1997; 10(3): 157-62.
  145. Anner BM, Moosmayer M, Imesch E. Mercury blocks Na-K-ATPase by a ligand-dependent and reversible mechanism. Am J Physiol. 1992; 262(5.2): F830-6.
  146. Anner BM, Moosmayer M. Mercury inhibits Na-K-ATPase primarily at the cytoplasmic side. Am J Physiol. 1992; 262(5.2): F84308.
  147. Wagner CA, Waldegger S, et al. Heavy metals inhibit Pi-induced currents through human brush-border NaPi-3 cotransporter in Xenopus oocytes. Am J Physiol. 1996; 271(4.2): F926-30.
  148. Lewis RN, Bowler K. Rat brain (Na+-K+)ATPase: Modulation of its ouabain-sensitive K+-PNPPase activity by thimerosal. Int J Biochem. 1983; 15(1): 5-7.
  149. Rajanna B, Hobson M, Harris L, Ware L, Chetty CS. Effects of cadmium and mercury on Na(+)-K(+) ATPase and uptake of 3H-dopamine in rat brain synaptosomes. Arch Int Physiol Biochem. 1990; 98(5): 291-6.
  150. Hobson M, Rajanna B. Influence of mercury on uptake of dopamine and norepinephrine. Toxicol Letters. 1985; 27(2-3): 7-14.
  151. McKay SJ, Reynolds JN, Racz WJ. Effects of mercury compounds on the spontaneous and potassium-evoked release of [3H] dopamine from mouse striatial slices. Can J Physiol Pharmacol. 1986; 64(12): 1507-14.
  152. Scheuhammer AM, Cherian MG. Effects of heavy metal cations, sulfhydryl reagents and other chemical agents on striatal D2 dopamine receptors. Biochem Pharmacol. 1985; 34(19): 3405-13.
  153. Hoyt KR, et al. Mechanisms of dopamine-induced cell death and differences from glutamate induced cell death. Exp Neurol. 1997; 143(2): 269-81.
  154. Offen D, et al. Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels. Neurology. 1998; 51(4): 1100-3.
  155. Huggins Applied Healing. Multiple sclerosis. Available at http://www.hugginsappliedhealing.com/ms.php. Accessed December 30, 2014.
  156. Huggins HA, Levy TE. Cerebrospinal fluid protein changes in MS after dental amalgam removal. Alternative Med Rev. 1998; 3(4): 295-300.
  157. Bucio L, et al. Uptake, cellular distribution and DNA damage produced by mercuric chloride in a human fetal hepatic cell line. Mutat Res. 1999; 423(1-2): 65-72.
  158. Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res. 2002; 70(5): 694-702.
  159. Snyder RD, Lachmann PJ. Thiol involvement in the inhibition of DNA repair by metals in mammalian cells. Source Mol Toxicol. 1989; 2(2): 117-28.
  160. Verschaeve L, et al. Comparative in vitro cytogenetic studies in mercury-exposed human lymphocytes. Mut Res. 1985; 157(2-3): 221-6.
  161. Verschaeve L. Genetic damage induced by low level mercury exposure. Envir Res. 1976; 12: 306-10.
  162. Hock C, et al. Increased blood mercury levels in patients with Alzheimer’s disease. J Neural Transm. 1998; 105(1): 59-68.
  163. Wilkinson LJ, Waring RH. Cysteine dioxygenase: Modulation of expression in human cell lines by cytokines and control of sulfate production. Toxicol In Vitro. 2002; 16(4): 481-3.
  164. Tanner CM, et al. Abnormal liver enzyme metabolism in Parkinson’s. Neurology. 1991; 41(5.2): 89-92.
  165. Heafield MT, et al. Plasma cysteine and sulfate levels in patients with motor neuron disease, Parkinson’s disease, and Alzheimer’s disease. Neurosci Lett. 1990; 110(1-2): 216-20.
  166. Pean A, et al. Pathways of cysteine metabolism in MND/ALS. J Neurol Sci. 1994; 124: 59-61.
  167. Steventon GB, et al. Xenobiotic metabolism in motor neuron disease. Lancet. 1988: 644-47.
  168. Gordon C, et al. Abnormal sulfur oxidation in systemic lupus erythrmatosus (SLE). Lancet. 1992; 339: 8784.
  169. Emory P, et al. Poor sulphoxidation in patients with rheumatoid arthritis. Ann Rheum Dis. 1992; 51(3): 318-20.
  170. Bradley H, et al. Sulfate metabolism is abnormal in patients with rheumatoid arthritis. Confirmation by in vivo biochemical findings. J Rheumatol. 1994; 21(7): 1192-6.
  171. Perry TL, et al. Hallevorden-Spatz disease: Cysteine accumulation and cysteine dioxygenase deficiency. Ann Neural. 1985; 18(4): 482-489.
  172. Freitas AJ, et al. Effects of Hg2+ and CH3Hg+ on Ca2+ fluxes in the rat brain. Brain Research. 1996; 738(2): 257-64.
  173. Yallapragoda PR, et al. Inhibition of calcium transport by Hg salts in rat cerebellum and cerebral cortex. J Appl Toxicol. 1996; 164(4): 325-30.
  174. Chavez E, et al. Mitochondrial calcium release by Hg+2. J Biol Chem. 1988; 263(8): 3582.
  175. Szucs A, et al. Effects of inorganic mercury and methylmercury on the ionic currents of cultured rat hippocampal neurons. Cell Mol Neurobiol. 1997; 17(3): 273-8.
  176. Busselberg D. Calcium channels as target sites of heavy metals. Toxicol Lett. 1995; 82-83: 255-61.
  177. Rossi AD, et al. Modifications of Ca2+ signaling by inorganic mercury in PC12 cells. FASEB J. 1993; 7: 1507-14.
  178. Engqvist A, et al. Speciation of mercury excreted in feces from individuals with amalgam fillings. Arch Environ Health. 1998; 53(3): 205-13.
  179. Boadi WY, et al. In vitro effect of mercury on enzyme activities and its accumulation in the first-trimester human placenta. Environ Res. 1992; 57(1): 96-106.
  180. Urbach J, et al. Effect of inorganic mercury on in vitro placental nutrient transfer and oxygen consumption. Reprod Toxicol. 1992; 6(1): 69-75.
  181. Karp W, Gale TF et al. Effect of mercuric acetate on selected enzymes of maternal and fetal hamsters. Environ Res. 1985; 36: 351-358.
  182. Karp WB, et al. Correlation of human placental enzymatic activity with tracemetal concentration in placenta. Environ Res. 1977; 13: 470-477.
  183. Boot JH. Effects of SH-blocking compounds on the energy metabolism and glucose uptake in isolated rat hepatocytes. Cell Struct Funct. 1995; 20(3): 233-8.
  184. Iioka H, et al. The effect of inorganic mercury on placental amino acid transport. Nippon Sanka Fujinka Gakkai Zasshi. 1987; 39(2): 202-6.
  185. Clauw DJ, The pathogenesis of chronic pain and fatigue syndromes: Fibromyalgia. Med Hypothesis. 1995; 44: 369-78.
  186. Hanson S. Fibromyalgia, glutamate, and mercury. Heavy Metal Bulletin. 1999; 4.
  187. Stejskal VDM, Danersund A, Lindvall A, et al. Metal-specific memory lymphoctes: biomarkers of sensitivity in man. Neuroendocrinology Letters. 1999.
  188. Prochazkova J, Sterzl I, Kucerova H, Bartova J, Stejskal VD. The beneficial effect of amalgam replacement on health in patients with autoimmunity. Neuroendocrinology Lett. 2004; 25(3): 211-8.
  189. Atchison WD. Effects of neurotoxicants on synaptic transmission. Neuroltoxicol Teratol. 1998; 10(5): 393-416.
  190. Sidransky H, Verney E. Influence of lead acetate and selected metal salts on tryptophan binding to rat hepatic nuclei. Toxicol Pathol. 1999; 27(4): 441-7.
  191. Shukla GS, Chandra SV. Effect of interaction of Mn2+withZn2+, Hg2+, and Cd2+ on some neurochemicals in rats. Toxicol Lett. 1982; 10(2-3): 163-8.
  192. Brouwer M, et al. Functional changes induced by heavy metal ions. Biochemistry. 1982; 21(20): 2529-38.
  193. Stejskal J, Stejskal V. The role of metals in autoimmune diseases and the link to neuroendocrinology. Neuroendocrinology Letters. 1999; 20: 345-358.
  194. Froissard P, et al. Role of glutathione metabolism in the glutamate-induced programmed cell death of neuronal cells. Eur J Pharmacol. 1997; 236(1): 93-99.
  195. Kim P, Choi BH. Selective inhibition of glutamate uptake by mercury in cultured mouse astrocytes. Yonsei Med J. 1995; 36(3): 299-305.
  196. Brookes N. In vitro evidence for the role of glutatmate in the CNS toxicity of mercury. Toxicology. 1992; 76(3): 245-56.
  197. Albrecht J, Matyja E. Glutamate: A potential mediator of inorganic mercury toxicity. Metab Brain Dis. 1996; 11: 175-84.
  198. Tirosh O, Sen CK, Roy S, Packer L. Cellular and mitochondrial changes in glutamate-induced HT4 neuronal cell death. Neuroscience. 2000; 97(3): 531-41.
  199. Munch G, Gerlach M, Sian J, Wong A, Riederer P. Advanced glycation end products in neurodegeneration: more than early markers of oxidative stress? Ann Neurol. 1998; 44(3.1): S85-8.
  200. Hu H, Abedi-Valugerdi M, Moller G. Pretreatment of lymphocytes with mercury in vitro induces a response in T cells from genetically determined low-responders and a shift of the interleukin profile. Immunology. 1997; 90(2): 198-204.
  201. Hu H, Moller G, Abedi-Valugerdi M. Major histocompatibility complex class II antigens are required for both cytokine production and proliferation induced by mercuric chloride in vitro. J Autoimmun. 1997; 10(5): 441-6.
  202. Hu H, Moller G, Abedi-Valugerdi M. Mechanism of mercury-induced autoimmunity: both T helper 1- and T helper 2-type responses are involved. Immunology. 1999; 96(3): 348-57.
  203. Hultman P, Johansson U, Turley SJ. Adverse immunological effects and autoimmunity induced by dental amalgam in mice. FASEB J. 1994; 8:1183-90.
  204. Pollard KM, Lee DK, Casiano CA. The autoimmunity-inducing xenobiotic mercury interacts with the autoantigen fibrillarin and modifies its molecular structure and antigenic properties. J Immunol. 1997; 158: 3421-8.
  205. Abedi-Valugerdi M, Hansson M, Moller G. Genetic control of resistance to mercury-induced immune/autoimmune activation. Scand J Immunol. 2001; 54(1-2): 190-7.
  206. Hultman P, Nielsen JB. The effect of toxicokinetics on murine mercury-induced autoimmunity. Environ Res. 1998; 77(2): 141-8.
  207. Hultman P, et al. Activation of the immune system and systemic immune-complex deposits in brown Norway rats with dental amalgam restorations. J Dent Res. 1998; 77(6): 1415-25.
  208. Fukino H, Hirai M, Hsueh YM, Yamane Y. Effect of zinc pretreatment on mercuric chloride-induced lipid peroxidation in the rat kidney. Toxicol Appl Pharmacol. 1984; 73(3): 395-401.
  209. Sutton KG, McRory JE, Guthrie H, Snutch TP. P/Q-type calcium channels mediate the activity-dependent feedback of syntaxin-1A. Nature. 1999; 401(6755): 800-4.
  210. Wojda U, Salinska E, Kuznicki J. Calcium ions in neuronal degeneration. IUBMB Life. 2008; 60(9): 575-90.
  211. Godfrey ME, Wojcik DP, Krone CA. Apolipoprotein E genotyping as a potential biomarker for mercury neurotoxicity. J Alzheimers Dis. 2003; 5(3): 189-95.
  212. Mutter J, Naumann J, Sadaghiani C, Schneider R, Walach H. Alzheimer disease: mercury as pathogenetic factor and apolipoprotein E as a moderator. Neuroendocrinology Letters. 2004; 25(5).
  213. Mutter J, Deth R. Does inorganic mercury play a role in Alzheimer’s disease? A systematic review and an integrated molecular mechanism. Journal of Alzheimer’s Disease. 2010.
  214. Olanow CW, Arendash GW. Metals and free radicals in neurodegeneration. Curr Opin Neurol. 1994; 7(6): 548-58.
  215. Troy CM, Shelanski ML. Down-regulation of copper/zinc superoxide dismutase causes apototic dealth in PC12 neuronal cells. Proc. National Acad Sci, USA. 1994, 91(14): 6384-7.
  216. Rothstein JD, Dristol LA, Hosier B, Brown RH, Kunci RW. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Nat Acad Sci, USA. 1994; 91(10): 4155-9.
  217. Beal MF. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Biofactors. 1999; 9(2-4): 262-6.
  218. DiMauro S, Moses LG; CoQ10 use leads to dramatic improvements in patients with muscular disorder. Neurology. April 2001.
  219. Schultz C, et al. CoQ10 slows progression of Parkinson’s disease. Archives of Neurology. 2002.
  220. Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci, USA. 1998; 95(15): 8892-7.
  221. Schulz JB, Matthews RT, Henshaw DR, Beal MF. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience. 1996; 71(4): 1043-8.
  222. Nagano S, Ogawa Y, Yanaghara T, Sakoda S. Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice. Neurosci Lett. 1999; 265(3): 159-62.
  223. Leonard BE. Inflammation, depression and dementia: Are they connected? Neurochem Res. 2007; 32(10): 1749-56.
  224. Walsh SJ, Rau LM. Autoimmune disease overlooked as a leading cause of death in women. Am J Public Health. 2000; 90: 1463-1466.
  225. Olivieri G, Brack C, Muller-Spahn F, et al. Mercury induces cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells. J Neurochem. 2000; 74(1): 231-6.
  226. Tabner BJ, Turnbull S, El-Agnaf OM, Allsop D. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease. Free Radic Biol Med. 2002; 32(11): 1076-83.
  227. Ho PI, Collins SC, et al. Homocysteine potentiates beta-amyloid neurotoxicity: Role of oxidative stress. J Neurochem. 2001; 78(2): 249-53.
  228. Rondeau V, Commenges D, H Jacqmin-Gadda, Dartigues JF. Relation between aluminum concentrations in drinking water and Alzheimer’s disease: An 8-year follow-up study. American Journal of Epidemiology. 2000; 152(1): 59-66.
  229. Gupta VB, Anitha S, Jagannatha Rao KS. Aluminum in Alzheimer’s disease: Are we still at a crossroad? Cell Mol Life Sci. 2005; 62(2): 143-58.
  230. Landner L, Lindestrom L. Copper in Society and the Environment. 2nd ed. 1999.
  231. Huang X, Cuajungco MP, et al. Cu(II) potentiation of Alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem. 1999; 274(52): 37111-6.
  232. Waggoner DJ, Bartnikas TB, Gitlin JD. The role of copper in neurodegenerative disease. Neurobiol Dis. 1999; 6(4): 221-30.
  233. Torsdottir G, Kristinsson J, Gudmundsson G, Snaedal J, Johannesson T. Copper, ceruloplasmin and superoxide dismustase (SOD) in amyotrophic lateral sclerosis. Pharmacol Toxicol. 2000; 87(3): 126-30.
  234. Estevez AG, Beckman JS, et al, Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science. 1999; 286(5449): 2498-500.
  235. Cookson MR, Shaw PJ. Oxidative stress and motor neurons disease. Brain Pathol. 1999; 9(1): 165-86.
  236. Kobayashi MS, Han D, Packer L. Antioxidants and herbal extracts protect HT-4 neuronal cells against glutamate-induced cytotoxicity. Free Radic Res. 2000; 32(2): 115-24.
  237. Bridi R, Crossetti FP, Steffen VM, Henriques AT. The antioxidant activity of standardized extract of Ginkgo biloba (EGb 761) in rats. Phytother Res. 2001; 15(5): 449-51.
  238. Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med. 1997; 22(1-2): 359-78.
  239. Whiteman M, Tritschler H, Halliwell B. Protection against peroxynitrite-dependent tyrosine nitration and alpha 1-antiproteinase inactivation by oxidized and reduced lipoic acid. FEBS Lett. 1996; 379(1): 74.
  240. Gregus Z, et al. Effect of lipoic acid on biliary excretion of glutathione and metals. Toxicol Appl Pharmacol. 1992; 114(1): 88-96.
  241. Li Y, Liu L, Barger SW, Mrak RE, Griffin WS. Vitamin E suppression of microglial activation is neuroprotective. J Neurosci Res. 2001; 66(2): 163-70.
  242. Kang JH, Eum WS. Enhanced oxidative damage by the familial amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismustase mutants. Biochem Biophys Acta. 2000; 1524(2-3): 162-70.
  243. Eum WS. Enhanced oxidative damage by the familial amyotrophic lateral sclerosis-associated Cu, Zn-superoxide dismutase mutants. Biochem Biophys Acta. 2000; 1524(2-3): 162-70.
  244. Liu H, Zhu H, Eggers DK, Nersissian AM, et al. Copper(2+) binding to the surface residue cysteine 111 of His46Arg human copper-zinc superoxide dismutase, a familial amyotrophic lateral sclerosis mutant. Biochemistry. 2000; 39(28): 8125-32.
  245. Wong PC, Gitlin JD, et al. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. Proc Natl Acad Sci, USA. 2000 Mar; 97(6): 2886-91.
  246. Kruman II, Pedersen WA, Springer JE, Mattson MP. ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp Neurol. 1999; 160(1): 28-39.
  247. Doble A. The role of excitotoxicity in neurodegenerative disease: Implications for therapy. Pharmacol Ther. 1999; 81(3): 163-221.
  248. Urushitani M, Shimohama S. N-methyl-D-aspartate receptor-mediated mitochondrial Ca(2+)overload in acute excitotoxic motor neuron death: a mechanism distinct from chronic neurotoxicity after Ca(2+) influx. J Neurosci Res. 2001; 63(5): 377-87.
  249. Cookson MR, Shaw PJ. Oxidative stress and motor neurons disease. Brain Pathol. 1999; 9(1): 165-86.
  250. Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer’s disease animal models. Alzheimer’s Dis. 2004; 6: 367-77.
  251. Shukla PK, Khanna VK, Khan MY, Srimal RC. Protective effect of curcumin against lead neurotoxicity in rat. Hum Exp Toxicol. 2003; 22: 653-8.
  252. Daniel S, Limson JL, Dairam A, Watkins GM, Daya S. Through metal binding, curcumin protects against lead- and cadmium-induced lipid peroxidation in rat brain homogenates and against lead-induced tissue damage in rat brain. J Inorg Biochem. 2004; 98: 266-75.
  253. Classen B. Vaccines are the largest cause of insulin-dependent diabetes in young children. Autoimmunity. 2002; 35(4): 247.
  254. Narayan KMV, Boyle JP. Lifetime risk for diabetes mellitus in the U.S. JAMA. 2003; 290(14): 1884-90.
  255. Kikuchi M, Kashii S, Honda Y, Tamura Y, Kaneda K, Akaike A. Protective effects of methylcobalamin, a vitamin B12 analog, against glutamate-induced neurotoxicity in retinal cell culture. Invest Ophthalmol Vis Sci. 1997; 38(5): 848-54.
  256. Waly M, Olteanu H, Deth RC, et al. Activation of methionine synthase by insulin-like growth factor-1 and dopamine: A target for neurodevelopmental toxins and thimerosal. Mol Psychiatry. 2004; 9(4): 358-70.
  257. Loubinoux J, Bisson-Boutelliez C, Miller N, Le Faou AE. Isolation of the provisionally named Desulfovibrio fairfieldensis from human periodontal pockets. Oral Microbiology and Immunology. 2002; 17(5): 321-323.
  258. Appel SH, Beers D, Siklos L, Engelhardt JI, Mosier DR. Calcium: The Darth Vader of ALS. Amyotroph Lateral Scler. 2001; 2(1): S47-54.
  259. Earl C, Chantry A, Mohammad N. Zinc ions stabilize the association of basic protein with brain myelin membranes. J Neurochem. 1988; 51: 718-24.
  260. Riccio P, Giovanneli S, Bobba A. Specificity of zinc binding to myelin basic protein. Neurochem Res. 1995; 20: 1107-13.
  261. Sanders B. The role of general and metal-specific cellular responses in protection and repair of metal-induced damage: stress proteins and metallothioneins. Chang L, ed. Toxicology of Metals. Lewis Publishers, CRC Press Inc; 1996: 835-52.
  262. Mendez-Alvarez E, Soto-Otero R, et al. Effects of aluminum and zinc on the oxidative stress caused by 6-hydroxydopamine autoxidation: Relevance for the pathogenesis of Parkinson’s disease. Biochim Biophys Acta. 2002; 1586(2): 155-68.
  263. Guermonprez L, Ducrocq C, Gaudry-Talarmain YM. Inhibition of acetylcholine synthesis and tyrosine nitration induced by peroxynitrite are differentially prevented by antioxidants. Mol Pharmacol. 2001; 60(4): 838-46.
  264. Mahboob M, Shireen KF, Atkinson A, Khan AT. Lipid peroxidation and antioxidant enzyme activity in different organs of mice exposed to low level of mercury. J Environ Sci Health B. 2001; 36(5): 687-97.
  265. Urushitani M, Shimohama S. The role of nitric oxide in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 2(2): 71-81.
  266. Torreilles F, Salman-Tabcheh S, Guerin M, Torreilles J. Neurodegenerative disorders: The role of peroxynitrite. Brain Res Brain Res Rev. 1999; 30(2): 153-63.
  267. Aoyama K, Matsubara K, Kobayashi S. Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases. Ann Neurol. 2000; 47(4): 524-7.
  268. Guermonprez L, Ducrocq C, Gaudry-Talarmain YM. Inhibition of acetylcholine synthesis and tyrosine nitration induced by peroxynitrite are differentially prevented by antioxidants. Mol Pharmacol. 2001; 60(4): 838-46.
  269. Laks, Dan, R. Assessment of chronic mercury exposure within the U.S. population, National Health and Nutrition Examination Survey, 1999–2006. Biometals. 2009.
  270. Laks DR, et al. Mercury has an affinity for pituitary hormones. Medical Hypotheses. 2009.
  271. Pritchard C, et al. Pollutants appear to be the cause of the huge rise in degenerative neurological conditions. Public Health. 2004.
  272. Mutter J, Daschner F, et al. Amalgam risk assessment with coverage of references up to 2005. Gesundheitswesen. 2005; 67(3): 204-16.
  273. Life Enhancement. Available at: http://www.life-enhancement.com/. Accessed December 30, 2014
  274. Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology. 1999; 117(5): 1155-63.
  275. Cave S, Mitchell D. What Your Doctor May Not Tell You about Children’s Vaccinations. Warner Books; 2001.
  276. Waly M, et al, Activation of methionine synthase by insulin-like growth factor-1 and dopamine: A target for neurodevelopmental toxins and thimerosal. Molecular Psychiatry. 2004: 1-13.
  277. Finefrock AE, Bush AI, Doraiswamy PM. Current status of metals as therapeutic targets in Alzheimer’s disease. J Am Geriatr Soc. 2003; 51(8): 1143-8.
  278. Doraiswamy PM, Finefrock AE. Metals in our minds: Therapeutic implications for neurodegenerative disorders. Lancet. 2004; 3(7): 431-4.
  279. Perry G, Sayre LM, Atwood CS, Castellani RJ, Cash AD, Rottkamp CA, et al. The role of iron and copper in the aetiology of neurodegenerative disorders. CNS Drugs. 2002; 16: 339-52.
  280. Dai X, Sun Y. Zhaofeng Copper (2) potentiation of Alzheimer’s A-(beta)1-40 cytotoxicity and transition on its secondary structure. Acta Biochimica et Biophysica Sinica. 1938; 11: 765-72.
  281. Liu G, Huang W, Moir RD, Vanderburg CR, Barry AI, Zicheng P, et al. Metal exposure and Alzheimer’s pathogenesis. J Structural Biol. 2005; 155: 45-51.
  282. Limson J, Nyokong T, Daya S.The interaction of melatonin and its precursors with aluminium, cadmium, copper, iron, lead, and zinc: An adsorptive voltammetric study. J Pineal Res. 1998; 24(1): 15-21.
  283. McIntyre RS, Soczynska JK, Kennedy SH, et al. Should Depressive Syndromes Be Reclassified as Metabolic Syndrome Type II? Ann Clin Psychiatry. 2007; 19(4): 257-64.
  284. Leonard BE. Inflammation, depression and dementia: are they connected? Neurochem Res. 2007 Oct; 32(10): 1749-56.
  285. Blayloc, RL. Immunoexcitotoxicity. Alt Ther Health Med. 2008; 14: 46-53.
  286. Klinghard D, Mercola J. Mercury toxicity and systemic elimination agents. J of Nutritional and Environmental Medicine. 2001; 11: 53-62.
  287. Rayssiguier Y, Gueux E, et al. High fructose consumption combined with low dietary magnesium intake may increase the incidence of the metabolic syndrome by inducing inflammation. Magnes Res. 2006; 19(4): 237-43.
  288. Bo S, Durazzo M, Pagano G. et al. Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. Am J Clin Nutr. 2006; 84(5): 1062-9.
  289. Guerrero-Romero F, Rodríguez-Morán. Hypomagnesemia, oxidative stress, inflammation, and metabolic syndrome. Diabetes Metab Res Rev. 2006; 22(6): 471-6.
  290. Dandona P. Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein. Mayo Clin Proc. 2008; 83(3): 333-42.
  291. Gill V, Singal P. Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications. Cell Biochem Biophys. 2007; 49(1): 48-63.
  292. Barnes DM, Kircher EA. Effects of mercuric chloride on glucose transport in 3T3-L1 adipocytes. Toxicol In Vitro. 2005; 19(2): 207-14.
  293. Barnes DM, Hanlon PR, Kircher EA. Effects of inorganic HgCl2 on adipogenesis. Toxicol Sci. 2003; 75(2): 368-77.
  294. Iturri SJ, Peña A. Heavy metal-induced inhibition of active transport in the rat small intestine in vitro: Interaction with other ions. Comp Biochem Physiol C. 1986; 84(2): 363-8.
  295. Klip A, Grinstein S, Biber J, Semenza G. Interaction of the sugar carrier of intestinal brush-border membranes with HgCl2. Biochim Biophys Acta. 1980; 598(1): 100-14.
  296. Gueux E, et al. High fructose consumption combined with low dietary magnesium intake may increase the incidence of the metabolic syndrome by inducing inflammation. Magnes Res. 2006; 19(4): 237-43.
  297. Bo S, Durazzo M, Pagano G, et al. Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. Am J Clin Nutr. 2006; 84(5): 1062-9.
  298. Rodríguez-Morán. Hypomagnesemia, oxidative stress, inflammation, and metabolic syndrome. Diabetes Metab Res Rev. 2006; 22(6): 471-6.
Print Friendly